课题基金 / 基金详情

项目摘要

项目成果

Daniel Gulbranson的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
Project Summary/Abstract Our goal is to advance our understanding and ability to treat Alzheimer's disease. Our lab discovered that tau reduction can prevent Aβ-induced activation of GSK3β, a kinase that is activated by many AD-relevant pathomechanisms and has been implicated in the hyperphosphorylation of tau. We will determine which of these mechanisms activate GSK3β in a tau-dependent manner and whether the activation involves direct interactions between tau and GSK3β. To prevent tau-dependent GSK3β activation, we propose to reduce overall tau levels. Tau reduction can prevent cognitive decline and neurodegeneration in mouse models of AD. We found that blocking the rho-associated protein kinase (ROCK) pathway reduces tau levels in primary cells and in adult mouse brain. To further explore this therapeutic strategy, we will use a new ROCK inhibitor that has high potency and good brain penetration in mouse models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluation and Disruption of Tau - GSK3β Vicious Cycle
  • 批准号:
    10398663
  • 项目类别:
  • 资助金额:
    $0.25万
  • 财政年份:
    2019
  • 负责人:
    Daniel Gulbranson
  • 依托单位:
Evaluation and Disruption of Tau - GSK3ò Vicious Cycle
  • 批准号:
    10237411
  • 项目类别:
  • 资助金额:
    $2.33万
  • 财政年份:
    2019
  • 负责人:
    Daniel Gulbranson
  • 依托单位:
海外基金